Hepatitis B Virus and Risk of Non-Hodgkin Lymphoma Hepatitis B Virus and Risk of Non-Hodgkin Lymphoma
Several prior studies have suggested that chronic HBV infection can increase the risk of non-Hodgkin's lymphoma. What's the current best evidence on this possible relationship?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 11, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Cases Transferred To Roundup MDL Bring Total Glyphosate Actions To More Than 500
SAN FRANCISCO - The Judicial Panel on Multidistrict Litigation (JPMDL) on Aug. 27 issued a conditional transfer order sending another 27 cases to the Roundup multidistrict litigation in the U.S. District Court for the Northern District of California, bring the total number of cases in the MDL in which the plaintiffs allege that their exposure to the Roundup herbicide caused them to develop non-Hodgkin lymphoma (NHL) to more than 500 (In Re: Roundup Products Liability Litigation, No. 2741, JPMDL). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - September 6, 2018 Category: Medical Law Source Type: news

Cancer: Costly non-Hodgkin lymphoma drug rejected for NHS use
NICE has rejected a new blood cancer drug, Yescarta, which is for the treatment of non-Hodgkin lymphoma, for NHS use due to the drug being too expensive. (Source: Daily Express - Health)
Source: Daily Express - Health - August 29, 2018 Category: Consumer Health News Source Type: news

NICE consults on expensive blood cancer treatment
NICE has invited comments and further evidence on a new treatment for aggressive subtypes of non-Hodgkin lymphoma called diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma that could lead to it being made available for use on the NHS. (Source: NHS Networks)
Source: NHS Networks - August 29, 2018 Category: UK Health Source Type: news

NICE rejects Gilead CAR-T cancer cell therapy
The company's CAR-T drug Yescarta, which had just received approval from the European Commission for two aggressive forms of non-Hodgkin lymphoma, was found to be too expensive according to Britain ’s state-funded health service. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 28, 2018 Category: Pharmaceuticals Source Type: news

Makers of a revolutionary cancer treatment asked to slash its 'eye-watering' cost
Nice today announced it was unable to approve a type of CAR-T therapy, called Yescarta, for thousands of non-Hodgkin lymphoma patients on the health service because it is so expensive. (Source: the Mail online | Health)
Source: the Mail online | Health - August 28, 2018 Category: Consumer Health News Source Type: news

Cancer patient who was awarded $289M in Monsanto case speaks out
Dewayne "Lee" Johnson alleges that his use of Monsanto's weed killer Roundup contributed to his non-Hodgkin's lymphoma (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 18, 2018 Category: Consumer Health News Source Type: news

Chemical giant ordered to pay $289M in Roundup cancer trial
"The simple fact is he is going to die," said the attorney who represented Dewayne Johnson, who has non-Hodgkin's lymphoma (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 11, 2018 Category: Consumer Health News Source Type: news

New Treatment for Non-Hodgkin Lymphoma Approved
Title: New Treatment for Non-Hodgkin Lymphoma ApprovedCategory: Health NewsCreated: 8/8/2018 12:00:00 AMLast Editorial Review: 8/9/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 9, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves Poteligeo for Rare Types of Non-Hodgkin Lymphoma
WEDNESDAY, Aug. 8, 2018 -- Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two rare types of non-Hodgkin lymphoma. The drug was approved to treat relapsed or refractory mycosis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 8, 2018 Category: Pharmaceuticals Source Type: news

New Treatment for Non-Hodgkin Lymphoma Approved
WEDNESDAY, Aug. 8, 2018 -- Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two types of non-Hodgkin lymphoma. The drug was approved to treat relapsed or refractory mycosis... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 8, 2018 Category: General Medicine Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or S ézary syndrome after at least one prior systemic therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 8, 2018 Category: American Health Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Carcinogenicity Of Glyphosate Debated At Opening Of Trial Against Monsanto
SAN FRANCISCO - The attorney for a man who claims that Monsanto Co. is responsible for his cancer on July 9 opened a bellwether trial in California state court by contending that the company has known since 1998 that its herbicide Roundup, which contains the active ingredient glyphosate, is connected to non-Hodgkin lymphoma (NHL), yet it failed to warn consumers (DeWayne Johnson v. Monsanto Company, No. CGC 16550128, Calif. Super., San Francisco Co.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 20, 2018 Category: Medical Law Source Type: news

Judge: Glyphosate Plaintiffs' Experts Are Admissible In Case Against Monsanto
SAN FRANCISCO - A federal judge in California on July 10 ruled that the experts for plaintiffs who have sued Monsanto Co. in multidistrict litigation related to the herbicide Roundup should be admitted because the plaintiffs have presented evidence from which a reasonable jury could conclude that glyphosate, the active ingredient in Roundup, can cause non-Hodgkin lymphoma (NHL) at "human-relevant doses" (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 20, 2018 Category: Medical Law Source Type: news

Children's Hospital maker space to use STEAM-inspired problem-solving
UPMC Children's Hospital of Pittsburgh will unveil Matt's Maker Space, where patients will be able to engage in STEAM-related problem-solving to both learn and distract them from their illnesses. The space is named to honor 12-year-old Matt Conover who died of non-Hodgkin's lymphoma, and the hospital will host an event at 1 p.m. Tuesday to celebrate its opening with community partners Children's Museum of Pittsburgh, Sen. John Heinz History Center, the Andy Warhol Museum, Mt. Lebanon Schoo l District… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 16, 2018 Category: Biotechnology Authors: Stacey Federoff Source Type: news

EPA official whitewashed glyphosate links to non-Hodgkin lymphoma in order to protect Monsanto profits
(Natural News) The EPA has been caught red-handed whitewashing studies of Monsanto’s cash cow, glyphosate. The federal agency purposely ignored data showing a clear connection between glyphosate and non-Hodgkin’s lymphoma. In addition to ignoring the obvious threat of glyphosate, agency regulators obscured the opinions of the Scientific Advisory Panel, charged with reviewing the EPA’s glyphosate... (Source: NaturalNews.com)
Source: NaturalNews.com - July 3, 2018 Category: Consumer Health News Source Type: news

Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
OSLO, 25 June, 2018 -- (Healthcare Sales & Marketing Network) -- Nordic Nanovector ASA (OSE: NANO) announces that Eduardo Bravo has been appointed as its Chief Executive Officer. Mr. Bravo brings more than 25 years' experience in the biopharmaceutical ... Biopharmaceuticals, Oncology, Personnel Nordic Nanovector, Betalutin, non-Hodgkin's lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

VHIO is the first Spanish site to conduct CAR T cell trial against lymphoma in Europe
(Vall d'Hebron Institute of Oncology) Launched: First international clinical trial with CAR T cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma (B-Cell NHL) in Europe.The trial has been designed to determine the efficacy and safety of JCAR017, a chimeric antigen receptor (CAR) T cell therapy, in the treatment of clinically selected adult patients with relapsed or refractory disease (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2018 Category: International Medicine & Public Health Source Type: news

Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma. The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma. “We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer T...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Antiviral Treatments Reduce Cancer Risk for HIV Patients
MONDAY, June 11, 2018 -- Long-term antiviral treatment cuts the risk of cancer in HIV patients as they age, a new study says. People with HIV are at increased risk for both AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma or invasive... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 11, 2018 Category: General Medicine Source Type: news

Monsanto Denies Liability, Says Roundup Is Non-Toxic, Non-Carcinogenic
SAN FRANCISCO - Monsanto Co. on May 29 filed another answer to one of the more than 400 lawsuits in the multidistrict litigation for Roundup, denying any liability for injuries - including non-Hodgkin lymphoma - that plaintiffs say were caused by exposure to the herbicide's active ingredient glyphosate (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - June 5, 2018 Category: Medical Law Source Type: news

Viewpoint: China has the upper hand in cancer cell therapy
Cheers went up last August when the U.S. Food and Drug Administration approved the world ’s first CAR-T cancer cell treatment, Novartis’ Kymriah, and again in October when it approved Gilead’s CAR-T treatment for non-Hodgkin's lymphoma. In CAR-T therapy, the immune system’s killer T cells are modified to target specific tumors, giving physicians a powerful new tool to treat canc er. But when it comes to the long-term development of this revolutionary treatment, China is poised to leapfrog… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 17, 2018 Category: Biotechnology Source Type: news

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016
This research has led to a Practice Changing Update on DynaMed Plus. Itarticle concludes that CHOP plus 131 I tositumomab and CHOP plus rituximab may have similar 5- and 10-year overall survival, but CHOP plus rituximab may improve 10-year progression-free survival in adults with advanced follicular lymphoma. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 16, 2018 Category: Consumer Health News Source Type: news

Breakthrough cancer therapy developed at Penn receives 2nd FDA approval
The Food and Drug Administration on Tuesday approved a second indication for a revolutionary cancer therapy initially developed by researchers at the University of Pennsylvania's Abramson Cancer Center. The FDA cleared Kymriah, a personalized cellular therapy marketed by Novartis, for use in patients with advanced non-Hodgkin's lymphoma. The FDA specifically approved Kymriah for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible fo r… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 1, 2018 Category: American Health Authors: John George Source Type: news

Breakthrough cancer therapy developed at Penn receives 2nd FDA approval
The Food and Drug Administration on Tuesday approved a second indication for a revolutionary cancer therapy initially developed by researchers at the University of Pennsylvania's Abramson Cancer Center. The FDA cleared Kymriah, a personalized cellular therapy marketed by Novartis, for use in patients with advanced non-Hodgkin's lymphoma. The FDA specifically approved Kymriah for the treatment of certain adult patients with relapsed or refractory diffuse large B-cell lymphoma. The American Cancer … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 1, 2018 Category: Biotechnology Authors: John George Source Type: news

Monsanto Liable For Fraud In Glyphosate Exposure That Caused Cancer, Woman Says
ST. LOUIS - An Alabama woman on March 28 sued Monsanto Co. in the U.S. District Court for the Eastern District of Missouri, seeking damages for fraud and misrepresentation, contending that her exposure to glyphosate, the active ingredient in the herbicide Roundup, caused her to develop non-Hodgkin lymphoma (NHL) (Betty L. Bolyard v. Monsanto Company, No. 18-469, E.D. Mo.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - April 3, 2018 Category: Medical Law Source Type: news

Karmanos Cancer Institute, first cancer center in Michigan to offer CAR-T Therapy for an aggressive type of non-Hodgkin Lymphoma
(Source: Karmanos Cancer Institute)
Source: Karmanos Cancer Institute - March 27, 2018 Category: Cancer & Oncology Source Type: news

Zimbabwe:33% of Cancers Aids Related
[263Chat] Aids related cancers namely Kaposi Sarcoma, Cervical Cancer, Non-Hodgkins Lymphoma and Squamous Cell Carcinoma of the conjunctiva continue to occupy high positions in cancer rankings, according to Zimbabwe National Cancer Registry report. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 22, 2018 Category: African Health Source Type: news

More Cases Are Reported of Unusual Cancer Linked to Breast Implants
Women with breast implants have an increased risk of a type of lymphoma that can usually be cured by surgery alone — but not always. (Source: NYT Health)
Source: NYT Health - March 21, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Implants Breasts Allergan Inc Breast Cancer Non-Hodgkin's Lymphoma Mentor Worldwide LLC Food and Drug Administration American Society for Aesthetic Plastic Surgery Source Type: news

Roswell Park to offer new lymphoma immunotherapy
Roswell Park Comprehensive Cancer Center will be among the first hospitals in the nation to offer a new T-cell therapy for lymphoma patients. The hospital was approved in late February to adminster Yescarta, an FDA-approved immunotherapy, to adult patients with a common type of non-Hodgkin lymphoma known as diffuse large B-cell lymphoma (DLBCL).  Manufactured by Kite, a Gilead company, the treatment uses the patient’s immune system to help fight the lymphoma using chimeric antigen receptor (CAR) T… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 6, 2018 Category: Biotechnology Authors: Tracey Drury Source Type: news

Study shows age doesn't affect survival in patients with non-Hodgkin lymphoma after HCT
(Be The Match) Results from a retrospective study presented at the 2018 BMT Tandem Meetings dispute age as a limiting factor to transplant eligibility, showing no differences in 4-year outcomes for patients older or younger than age 65. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2018 Category: Cancer & Oncology Source Type: news

For one early adopter, CAR T therapy means 18 months cancer-free and counting
For as long as he can remember, Josh Feldman has eagerly embraced the latest technology.Decades ago, his family was the first one on the block with a VCR. Years later, when television went hi-def, he acquired a big-screen TV and signed up for HD service.So after he was diagnosed with lymphoma, it was only natural that Feldman was driven to join clinical trials for a promising new treatment. He would become one of the first UCLA Health patients to receive CAR T therapy. When nothing else worked, the treatment beat back cancer and filled his life with new hope.“Years ago, while doing my own reading after my diagnosis, ...
Source: UCLA Newsroom: Health Sciences - February 14, 2018 Category: Universities & Medical Training Source Type: news

Maryland governor announces he has 'non-serious skin cancer'
Maryland Gov. Larry Hogan, who says he's in remission from non-Hodgkin's lymphoma, diagnosed with "non-serious skin cancer." (Source: ABC News: Health)
Source: ABC News: Health - February 1, 2018 Category: Consumer Health News Tags: Health Source Type: news

Maryland governor announces he has 'nonserious skin cancer'
Maryland Gov. Larry Hogan, who says he remains in complete remission from non-Hodgkin's lymphoma, says he has been diagnosed with "non-serious skin cancer." (Source: ABC News: Health)
Source: ABC News: Health - February 1, 2018 Category: Consumer Health News Tags: Health Source Type: news

Monsanto: Roundup Claims Fail For Lack Of Evidence About Glyphosate's Toxicity
SAN FRANCISCO - Monsanto Co. filed an answer in the multidistrict litigation for Roundup in California federal court on Jan. 16 denying that exposure to the herbicide "did or could have caused" non-Hodgkin lymphoma (NHL) as alleged by a specific plaintiff (In Re: Roundup Products Liability Litigation [Kevin McNew v. Monsanto Co.], MDL No. 2741, No. 17-6858, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - January 23, 2018 Category: Medical Law Source Type: news

Three generations of the same family all had cancer
Joanne Moss, 49, from Washingborough, Lincolnshire, was diagnosed with the blood cancer Non-Hodgkin Lymphoma in 2010 but received the all clear after six months of treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - January 4, 2018 Category: Consumer Health News Source Type: news

Global CAR T therapy trial shows high rates of durable remission for NHL
(University of Pennsylvania School of Medicine) In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah ™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients. Results from a global, multisite trial will be presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta (Abstract #577). Results from the single-site study, with follow-up extending past two years, will be published today in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2017 Category: Cancer & Oncology Source Type: news

Shut-off switch for lymphoma
(Technical University of Munich (TUM)) Safety switches that automatically stop the device for example before it overheats are built into many electrical appliances. Cells are also equipped with such 'emergency stop' functions. They make sure that a defective cell doesn't become a tumor cell. A team from Technical University of Munich has now discovered such a switch in T cells. These results can help to find new therapies against T cell Non-Hodgkin's lymphoma triggered by defective immune cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2017 Category: Cancer & Oncology Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Media News - November 17, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Investor Update - November 17, 2017 Category: Pharmaceuticals Source Type: news

HBV Infection and Development of Non-hodgkin Lymphoma HBV Infection and Development of Non-hodgkin Lymphoma
This study investigated the association of HBV infection and risk of non-Hodgkin's lymphoma. Might HBV vaccination reduce the risk in certain populations?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Glyphosate Exposure Causes Non-Hodgkin Lymphoma, Plaintiffs Say
SAN FRANCISCO - The plaintiffs in the multidistrict litigation for the herbicide Roundup on Oct. 27 filed a brief in California federal court, contending that there is "overwhelming evidence - whether it be the epidemiology, toxicology, or mechanistic data - that exposure to glyphosate-based formulations (GBFs) causes" non-Hodgkin lymphoma (NHL) (In re: Roundup Products Liability Litigation, No. 2741 MDL, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - November 8, 2017 Category: Medical Law Source Type: news

New treatment for adults with mantle cell lymphoma approved
The U.S. Food and Drug Administration today approved a new treatment for adult patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 31, 2017 Category: Consumer Health News Source Type: news

AstraZeneca wins US approval for lymphoma drug
U.S. regulators have approved a new treatment for patients with a rare form of non-Hodgkin lymphoma (Source: ABC News: Health)
Source: ABC News: Health - October 31, 2017 Category: Consumer Health News Tags: Health Source Type: news

Calquence Approved for Mantle Cell Lymphoma
TUESDAY, Oct. 31, 2017 -- Calquence (acalabrutinib) has been approved by the U.S. Food and Drug Administration to treat adults with mantle cell lymphoma. Mantle cell is an aggressive, fast-growing non-Hodgkin lymphoma, a cancer of the lymph system.... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 31, 2017 Category: General Medicine Source Type: news

Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma
ROCHESTER, Minn. ? Mayo Clinic announced today that its Rochester campus is one of 16 cancer centers nationally selected to provide chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for adults with?B-cell non-Hodgkin lymphoma?who have not responded to, or have relapsed, after two or more lines of treatment. The therapy, called axicabtagene ciloleucel (Yescarta), is [...] (Source: Mayo Clinic Business News)
Source: Mayo Clinic Business News - October 31, 2017 Category: Pharmaceuticals Source Type: news

Groundbreaking new cancer treatment approved
A second version of a new cancer treatment that uses a patient's own cells to fight non-Hodgkin's lymphoma has been approved by the FDA. Now 15,000 people may be eligible for the treatment. Dr. Tara Narula reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 23, 2017 Category: Consumer Health News Source Type: news

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
The U.S. Food and Drug Administration approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL). (Source: World Pharma News)
Source: World Pharma News - October 20, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Kite wins FDA approval for first adult CAR-T cell therapy
More than a month before it was due to make a decision, the FDA yesterday approved a CAR-T cell therapy from Kite Pharma (NSDQ:KITE) – the first of its kind for adults. The therapy, which is made from a patient’s own cells, is designed to treat adults with non-Hodgkin lymphoma who have failed at least two other treatments. Get the full story at our sister site, Drug Delivery Business News. The post Kite wins FDA approval for first adult CAR-T cell therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Oncology Regulatory/Compliance Wall Street Beat Gilead Sciences kitepharma Source Type: news